Earthpharm Technologies — Preclinical oral therapeutics for diabetic neuropathy

Earthpharm Technologies is a preclinical-stage TechBio company based in Bengaluru, India, engineering disease-modifying oral therapeutics for diabetic peripheral neuropathy (DPN). The programme is angel-funded and entering the in-vivo validation phase.

Our approach engages three regulatory nodes simultaneously — SIRT1, Nrf2 and AMPK — via a standardised clinical botanical matrix delivered through a proprietary sub-100nm nanocarrier system. In-silico thermodynamic screens report a lowest binding affinity of −10.4 kcal mol⁻¹. In-vitro work has demonstrated zero cytotoxicity and active quenching of reactive oxygen species (ROS) under high-glucose oxidative stress.

The commercialisation strategy runs on two parallel regulatory tracks: the CDSCO Phytopharmaceutical pathway for the Indian market, and the FDA 505(b)(2) pathway for a global out-licensing window.

Earthpharm operates as a resident bio-incubatee at the Centre for Cellular and Molecular Platforms (C-CAMP), Bangalore Life Science Cluster — a Department of Biotechnology initiative, Government of India. The company is a member of the K-SAP BIO 50 2026 cohort of the Karnataka Startup Advancement Programme, and maintains a research affiliation with the Central Sericultural Research & Training Institute (CSRTI) under the Central Silk Board, Ministry of Textiles, Government of India.

Earthpharm Technologies
Preclinical · Angel-funded · In-vivo entering

Where the nerve goes dark,
we bring it back.

An oral, disease-modifying therapeutic for diabetic neuropathy, the condition that develops in one of every two people living with diabetes, and drives more amputations than any other non-traumatic cause worldwide.

Read the science Partner with us
Continue
Earthpharm emblem

Earthpharm Technologies

We are engineering disease-modifying
oral therapeutics for diabetic neuropathy.

Diabetic neuropathy progresses because of an oxidative cascade no single-molecule drug interrupts at its source. Our standardised clinical botanical matrix engages three regulatory nodes simultaneously — SIRT1, Nrf2 and AMPK — and is delivered through a proprietary sub-100nm nanocarrier system that crosses to the affected tissue.

Round

Angel-funded

Phase

In-vivo entering

Delivery

Sub-100nm nanocarrier

Pathway

CDSCO · FDA 505(b)(2)

Institutional Residence

Built inside India’s premier
deep-tech life-sciences infrastructure.

Earthpharm operates from the Bangalore Life Science Cluster as a resident bio-incubatee at C-CAMP — a Department of Biotechnology initiative that has supported over 450 deep-tech health startups — and is a member of the K-SAP BIO 50 2026 cohort. Work is conducted in affiliation with government R&D infrastructure across the Departments of Biotechnology and Textiles.

K-SAP BIO 50

2026 cohort

K-SAP BIO 50

Karnataka Startup Advancement Programme

Dept. of IT, BT & S&T, Government of Karnataka

C-CAMP

Implementing institution · Resident bio-incubatee

C-CAMP

Centre for Cellular and Molecular Platforms

Bangalore Life Science Cluster · DBT, Govt of India

CSRTI · Central Silk Board

Research affiliation

CSRTI · Central Silk Board

Central Sericultural Research & Training Institute

Ministry of Textiles, Government of India

Open a conversation Partnership · Investor relations · Scientific collaboration

The Unmet Need

The world’s largest population of chronic neuropathic pain
has no disease-modifying therapy.

Move your cursor across the field. Each clinical fact is silent until you attend to it — the same gesture our therapeutic asks of the disease itself.

How patients describe it

burning.stabbing.tingling.numbness.allodynia.weakness.
Standard of Care Pregabalin · Gabapentin · Duloxetine · Tricyclics
Real-world outcomes ≤ 50% pain reduction  ·  Sedation  ·  Dependence  ·  Underdiagnosed  ·  Undertreated

Sources — IDF Diabetes Atlas, 11th edition (2024)  ·  NeuPSIG / IASP guidelines on neuropathic pain pharmacotherapy

Existing first-line treatments — pregabalin, gabapentin, duloxetine, tricyclic antidepressants — suppress symptoms without modifying the underlying oxidative cascade. Even with a “good” outcome, 30–50% pain reduction is the ceiling. The disease itself continues.

Earthpharm is engineering oral therapeutics designed to interrupt the upstream mechanism — not the downstream signal.

The Team

Founders & Advisory Board

Founding Team

Co-Founder & CEO

Nitin Krishna

Previously a content specialist at Meta. Leads GTM across both commercialisation tracks, fundraising (SISFS, NSRCEL, SAMRIDH), and institutional partnerships.

Co-Founder & CSO

Dr. Ravindra Zirmire

PhD, National Centre for Biological Sciences. Leads R&D direction, mechanistic validation (in-silico docking, in-vitro enzyme inhibition), and regulatory science for CDSCO Phytopharmaceutical and FDA 505(b)(2) pathways.

Co-Founder & COO

Nanjesh Patel

Owns investor relations and fundraising alongside upstream operations and supply chain — API and raw botanical sourcing, batch procurement across B1–B4, and operational lab logistics.

Scientific Execution

Lead Lab Scientist

Prarthana M S

Executes the wet-lab extraction protocols, the HPLC standardisation pipeline (six marker molecules across batches B1–B4), and the proprietary sub-100nm nano-encapsulation protocols for comparative bioavailability testing.

Advisory Counsel

Pharmaceutical Strategy & CMC

Dr. Andy Anantha

President & CEO · AVA Pharma Consultants

Three decades of CMC development across novel chemical entities and generics. Previously Vice President of Pharmaceutical Development & Quality at vTv Therapeutics, where lead candidates were progressed through IND, Phase 1, 2 and Phase 3; earlier, General Manager of Research at Torrent Pharma. PhD in Chemistry & Biochemistry (drug–DNA interactions), Seton Hall University.

Legal, IP & Regulatory Counsel

Shubhendu Anand

Founding Partner · Senior Advocate, Supreme Court of India

Chevening Scholar and graduate of Queen Mary University of London, specialised in Intellectual Property Law. Advises technology, healthcare and start-up clients on regulatory compliance, IP protection and contractual negotiation across IPR, medical law, and Technology-Media-Telecommunications. Represents clients at the Supreme Court of India, multiple high courts, the National Green Tribunal and arbitral institutions.